A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Adriamycin is an antineoplastic agent used in a wide variety of malignancies. Its use is limited because of a cumulative, dose-dependent irreversible cardiomyopathy. We report a case of adriamycin-induced cardiomyopathy, after he had undergone chemotherapy for Hodgin lymphoma. The patient had no cardiac risk factors, and neither laboratory nor imaging findings suggested myocarditis or dilated cardiomyopathy. Echocardiographic findings and differential diagnosis led us to attribute his conditiondoi:10.14740/jmc2132w fatcat:d22gekcmhbgxffk32ln4ighcte